• News
  • Updated: July 27, 2022

Institute Pledges Support For AfDB’s Pharmaceutical Foundation

The National Institute for Pharmaceutical Research and Development (NIPRD) has promised to support the African Pharmaceutical Technology Foundation recently approved by the African Development Bank’s (AFDB) Board of Directors.

Dr Obi Adigwe, NIPRD’s Director-General, revealed this in a statement issued on Wednesday in Lagos.

According to him, the aim of the Foundation is to enhance Africa’s access to technologies that underpin the manufacture of medicines, vaccines, and other pharmaceutical products.

“After the COVID-19 outbreak, NIPRD emerged as a huge contributor to the national and global response.

“NIPRD provided the internationally-acclaimed analysis that underpinned many African governments’ categorical position on the Madagascan COVID-19 organics preparation.

“This analysis went viral internationally with scientists and policymakers around the world referencing NIPRD’s seminal work on the product with their work; a multitude of lives on the continent were saved.

“Africa conserved millions of dollars that would otherwise have been expended on an unverified product, and research and development resources were prioritised for more effective solutions," he stated.


Related Topics

Join our Telegram platform to get news update Join Now
Felicia Abisola  Olamiji
Felicia Abisola Olamiji

  A graduate of English Language from Olabisi Onabanjo University, passionate about learning new...

More From this Author


glaxo smithkline consumer nig. plc Health Care

GlaxoSmithKline Consumer Nigeria Plc was incorporated in Nigeria on 23rd June 19...

ekocorp plc Health Care

Ekocorp PLC began operations in 1977 as Mercy Specialist Clinic. Within a few ye...

neimeth international pharmaceuticals plc Health Care

Neimeth International Pharmaceutical Plc was founded in 1957. The company is th...

pharma-deko plc Health Care

Pharma- Deko Plc formerly known as Parke- Davis Company started in Nigeria in 19...


0 Comment(s)


See this post in...